口服Xa因子抑制剂转换为普通肝素输注时的抗凝监测策略
本文综述口服Xa因子抑制剂对凝血监测试验的影响,重点讨论转换为静脉肝素治疗时的监测问题。文献回顾显示,口服Xa因子抑制剂残留效应可显著干扰显色抗Xa试验,但对整体凝血试验(aPTT或PT)影响轻微至中度。因此转换期间考虑使用aPTT监测可能更为审慎。
要点
- 口服Xa因子抑制剂残留效应显著干扰抗Xa试验准确性。
- 整体凝血试验(aPTT/PT)受影响程度较轻。
- 转换至静脉普通肝素时宜考虑用aPTT监测抗凝。
核心结论
- 口服Xa因子抑制剂影响抗Xa试验结果准确性,整体凝血试验受影响程度较轻。
- 从口服Xa因子抑制剂转换为静脉普通肝素输注期间,考虑使用aPTT监测可能更为审慎。
研究设计与样本
- 本文为文献综述,检索并汇总已发表证据,评估口服Xa因子抑制剂对抗凝监测试验的影响。
主要发现
- 口服Xa因子抑制剂残留效应可对现有显色抗Xa试验产生显著干扰。
- 口服Xa因子抑制剂残留效应对测量aPTT或PT的整体凝血试验影响为轻微至中度。
- 阿哌沙班、艾多沙班和利伐沙班的厂家标签未就转换至静脉普通肝素时的监测问题提供具体指导。
临床怎么用
- 住院患者从口服Xa因子抑制剂转换为静脉普通肝素输注时,可考虑采用aPTT而非抗Xa试验进行抗凝监测。
- 临床医生应意识到抗Xa试验结果可能因口服Xa因子抑制剂残留效应而不可量化或不准确,避免不必要的普通肝素剂量下调。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Published evidence regarding the effects of oral factor Xa inhibitors on anticoagulation monitoring tests is reviewed with a focus on monitoring concerns that can arise during transitions to i.v. heparin therapy. SUMMARY: Assays that measure inhibition of factor Xa activity (i.e., anti-Xa assays) are widely used in U.S. institutions to monitor i.v. heparin therapy and, in some cases, for monitoring other types of anticoagulation therapy. Clinicians have raised concerns that the use of anti-Xa assays to monitor heparin levels in hospitalized patients who must be transitioned from oral factor Xa inhibitor therapy to i.v. unfractionated heparin (UFH) infusions could yield unquantifiable or inaccurate results, leading to unnecessary UFH dose reductions and potential treatment failures; the manufacturer labeling of oral factor Xa inhibitors (apixaban, edoxaban, and rivaroxaban) does not provide specific guidance on this issue. Results of a literature review indicated that residual effects of oral factor Xa inhibitor use can result in substantial interference with the currently available chromogenic anti-Xa assays but negligible to moderate effects on global coagulation assays, which measure activated partial thromboplastin time (aPTT) or prothrombin time. Therefore, during the transition from an oral factor Xa inhibitor to i.v. UFH therapy, it may be prudent to consider an aPTT assay for anticoagulation monitoring. CONCLUSION: The use of oral factor Xa inhibitors appears to affect the accuracy of anti-Xa assay results, with results of global coagulation assays affected to a lesser degree.
引用
- Faust AC, Kanyer D, Wittkowsky AK, et al. Managing transitions from oral factor Xa inhibitors to unfractionated heparin infusions. Am J Health Syst Pharm. 2016. PMID: 27919873
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。